Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome

J Gastroenterol Hepatol. 2009 Nov;24(11):1707-9. doi: 10.1111/j.1440-1746.2009.06034.x.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Hemodynamics / drug effects*
  • Hepatorenal Syndrome / drug therapy*
  • Hepatorenal Syndrome / etiology
  • Hepatorenal Syndrome / physiopathology
  • Humans
  • Hypertension, Portal / drug therapy*
  • Hypertension, Portal / etiology
  • Hypertension, Portal / physiopathology
  • Liver Circulation / drug effects
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / physiopathology
  • Lypressin / analogs & derivatives*
  • Lypressin / therapeutic use
  • Renal Circulation / drug effects
  • Terlipressin
  • Treatment Outcome
  • Vasoconstrictor Agents / therapeutic use*

Substances

  • Vasoconstrictor Agents
  • Lypressin
  • Terlipressin